[CAL-101,a novel agent of targeted therapy in hematological malignancies].
CAL-101 is a selective inhibitor of the phosphatidylinositol-3 kinase (PI3K), it inhibits the survival, proliferation and migration of tumor cells by directly inducing apoptosis and inhibiting micro-environmental interactions. It has been determined that the P110δ isoforms of PI3K expressed primarily in cells of hematopoietic lineage, such as B and T cells. This review focuses on the target, mechanism of action, the use and prospect of CAL-101 in tumors of blood and lymph systems.
Department of Hematology, Tianjin Medical University Cancer Institue and Hospial, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Thearpy, Tianjin 300060, China.
Chan-Juan
CJ
Li
Department of Hematology, Tianjin Medical University Cancer Institue and Hospial, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Thearpy, Tianjin 300060, China.
Qing
Q
Zhang
Department of Hematology, Tianjin Medical University Cancer Institue and Hospial, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Thearpy, Tianjin 300060, China. E-mail: yizhuozhang@163.com.
Yi-Zhuo
YZ
Zhang
D000818:Animals; D019337:Hematologic Neoplasms / Q000188:drug therapy*; D006801:Humans; D000081082:Phosphoinositide-3 Kinase Inhibitors; D011687:Purines / Q000494:pharmacology / Q000627:therapeutic use*; D052999:Quinazolinones / Q000494:pharmacology / Q000627:therapeutic use*; D015398:Signal Transduction / Q000187:drug effects
D000081082:Phosphoinositide-3 Kinase Inhibitors; D011687:Purines; D052999:Quinazolinones; C552946:idelalisib